Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 2Multiple Endocrine Neoplasia Type 1 1Heart Failure 1Essential Hypertension 1Cardiotoxicity 1Barrett Esophagus 1

Interventions

Fulvestrant 5Exercise 5Eating 5Standard of Care 3Sodium Chloride 3Diet 3Alpelisib 3ribociclib 2gallium Ga 68 dotatate 2exemestane 2Vitamin D 2Tamoxifen 2Magnetic Resonance Spectroscopy 2Letrozole 2Ethanol 2Blood Specimen Collection 2Anastrozole 2zopiclone 1ziprasidone 1veliparib 1testosterone undecanoate 1testosterone enanthate 1pazopanib 1mirabegron 1methyl hydroxyethyl cellulose 1lenvatinib 1fluorocholine 1evolocumab 1dimethandrolone-undecanoate 1cyclopropapyrroloindole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 1 × candesartan × Clear all
NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡